ClinicalTrials.gg
RecruitingNCT06495021Updated Aug 11, 2026

How OMT Benefits Newly Diagnosed Patients With Respiratory Illness When Given Alongside Other Standard Care.

An interventional study of Lymphatic Pump Osteopathic Manipulative Therapy in Pneumonia, Sinusitis and Bronchitis, sponsored by Geisinger Clinic. Recruiting at 1 site in United States. Open to participants aged 65 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-08-11.

Sponsored by Geisinger Clinic · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 10 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
68
Allocation
Randomized
Ages
65 Years to 100 Years
Sex
All
01

Study summary

This study is to see Osteopathic Manipulative Therapy, or OMT, can aid in treating patients being seen for respiratory illness and associated symptoms. The hypothesis is that the addition of OMT therapy, alongside other standard care (such as a medication), can help lessen patient symptoms sooner than just other treatment alone, and the duration of the condition will shorten as well.

Read the detailed description

Respiratory illness is a common complaint seen routinely in primary care. Illness is a common cause of reduced productivity, general discomfort and missed time from work. Osteopathic manual therapy (OMT) and the lymphatic pump is used frequently among osteopathic physicians to treat patients with infections. Many osteopathic physicians have anecdotal reports of patient having reduced respiratory symptoms reported in follow up care from patients. OMT is a useful, low-cost treatment and can help reduce duration of illness symptoms, improve patients' comfort and accelerate their return to their productive lives.

There have been few studies on an outpatient level quantifying this improvement. Previous research in other models have showed benefits of OMT to help reduce illness. Studies in a rat model have shown reduced S. pneumonia bacterial load in the lung after lymphatic pump. Additional rat studies demonstrated improved benefit with lymphatic pump in addition to antibiotic treatment. In a dog model, lymphatic pump has been shown to increase cytokine flow to the thoracic duct. In humans, OMT has shown to improve secretory immunoglobulin A levels in stressed student population. In the hospital setting, OMT for patients with pneumonia has shown to decrease hospital length of stay 5. OMT has been a known useful additional treatment to pneumonia, however there are few prospective studies on treatment of pneumonia and respiratory illness in the outpatient setting.

This study is designed to support evidence that patients with a recent diagnosis of upper respiratory illness, sinusitis, bronchitis, or pneumonia who receive lymphatic pump OMT experience reduced severity and length of symptoms. After informed consent, patients of ages 65-100 years of age who are diagnosed with a respiratory illness will be randomized to either standard care without OMT, or standard care plus OMT. Patients will be provided an electronic survey to quantify symptoms of cough, congestion, and malaise on both the day of illness diagnosis followed by the same survey 5 days later. Survey results comparing day of diagnosis and 5 days later will be recorded in a secure database and analyzed with appropriate statistical testing. The goal of this study is to show how the lymphatic pump can reduce both severity and duration of symptoms related to respiratory illness.

02

Conditions studied

  • Pneumonia
  • Sinusitis
  • Bronchitis
  • Respiratory Disease
  • Respiratory Tract Infections

Keywords

  • Osteopathic Manual Therapy
  • Respiratory Illness
  • OMT
03

In context

Pneumonia

1,564 studies on the registry are indexed under Pneumonia; 265 are open to participants now.

This study's planned enrollment of 68 is below the median of 129 across 975 interventional studies indexed under Pneumonia.

Browse Pneumonia studies →

Lead sponsor

Geisinger Clinic is the lead sponsor of 127 studies on the registry; 17 are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 7 (78%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
65 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients being seen for respiratory illness symptoms at Geisinger 65-Forward Buckhorn, PA clinic for care.
  • Patients age of 65-100
  • New diagnosis of upper respiratory illness, sinusitis, bronchitis, or pneumonia during outpatient visit.

Exclusion criteria

Exclusion Criteria:

  • Patients that have a healing fracture, including the spine, pelvis, shoulder, ribs, vertebrae, or extremities.
  • Patients actively receiving any type of cancer treatment
  • Patients with active or previously diagnosed liver disease.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
68 participants (estimated)

Study arms

  • No intervention
    Control

    Patients in the control group will receive normal standard care, including any prescriptions, follow-up instructions, etc., as given by the provider to help treat their condition.

  • Experimental
    Treatment

    Patients will receive lymphatic pump OMT therapy in addition to other standard care (similar to the control patients, this would be a medication, follow-up instructions, etc.)

    Procedure: Lymphatic Pump Osteopathic Manipulative Therapy

Interventions

  • ProcedureLymphatic Pump Osteopathic Manipulative Therapy

    OMT is a series of manual pressure and physical stimulation among various parts of the body to stimulate fluid movement and immune response in patients with various symptoms and disease. This may help with conditions such as edema, clearance of infections, facilitate healing and circulation, and bolster the immune response. Specifically, the lymphatic pump type of OMT targets the head, neck, thoracic region, lumbar and sacral regions, pelvis, arms, legs, and abdomen.

    Also known as: Lymphatic Pump OMT

06

What researchers measure

Primary outcomes

  1. To address the magnitude in which lymphatic pump OMT improves respiratory illness symptom severity and overall sickness duration when combined with standard care treatment.

    Survey given to patients will provide feedback to capture their symptom severity at the time of diagnosis and 5 days post-diagnosis

    Time frame: Through study completion of up to one year.

07

Study locations

1 of 1 sites recruiting
  • Geisinger 65-Forward, Buckhorn
    Bloomsburg, Pennsylvania 17815, United States
    Recruiting
    • Margaret Moore, DO · ContactMmoore9@geisinger.edu · 570-416-5435
    • Margaret Moore, DO · Principal investigator
08

References and documents

Publications

  • Creasy C, Schander A, Orlowski A, Hodge LM. Thoracic and abdominal lymphatic pump techniques inhibit the growth of S. pneumoniae bacteria in the lungs of rats. Lymphat Res Biol. 2013 Sep;11(3):183-6. doi: 10.1089/lrb.2013.0007. Epub 2013 Sep 11. PubMed 24024572 ↗
  • Hodge LM, Creasy C, Carter K, Orlowski A, Schander A, King HH. Lymphatic pump treatment as an adjunct to antibiotics for pneumonia in a rat model. J Am Osteopath Assoc. 2015 May;115(5):306-16. doi: 10.7556/jaoa.2015.061. PubMed 25938525 ↗
  • Knott EM, Tune JD, Stoll ST, Downey HF. Increased lymphatic flow in the thoracic duct during manipulative intervention. J Am Osteopath Assoc. 2005 Oct;105(10):447-56. PubMed 16314677 ↗
  • Saggio G, Docimo S, Pilc J, Norton J, Gilliar W. Impact of osteopathic manipulative treatment on secretory immunoglobulin a levels in a stressed population. J Am Osteopath Assoc. 2011 Mar;111(3):143-7. PubMed 21464262 ↗
  • Noll DR, Degenhardt BF, Fossum C, Hensel K. Clinical and research protocol for osteopathic manipulative treatment of elderly patients with pneumonia. J Am Osteopath Assoc. 2008 Sep;108(9):508-16. PubMed 18806080 ↗
  • Noll DR, Degenhardt BF, Johnson JC. Multicenter Osteopathic Pneumonia Study in the Elderly: Subgroup Analysis on Hospital Length of Stay, Ventilator-Dependent Respiratory Failure Rate, and In-hospital Mortality Rate. J Am Osteopath Assoc. 2016 Sep 1;116(9):574-87. doi: 10.7556/jaoa.2016.117. PubMed 27571294 ↗
  • Yao S, Hassani J, Gagne M, George G, Gilliar W. Osteopathic manipulative treatment as a useful adjunctive tool for pneumonia. J Vis Exp. 2014 May 6;(87):50687. doi: 10.3791/50687. PubMed 24836893 ↗
  • Noll DR. The short-term effect of a lymphatic pump protocol on blood cell counts in nursing home residents with limited mobility: a pilot study. J Am Osteopath Assoc. 2013 Jul;113(7):520-8. doi: 10.7556/jaoa.2013.003. PubMed 23843375 ↗
  • Becker AD. Osteopathic treatment of the common cold. 1937. J Am Osteopath Assoc. 2001 Aug;101(8):461-3. No abstract available. PubMed 11534526 ↗

Individual participant data

Plan to share: No — There is no direct intent to share individual participant data related to this study. However, per institute policy, records of data generated during this study will be de-identified and will be kept for at least 6 years within the institutes secured database and then destroyed. Prior to destruction, the data will have the OPTION of being used for other Geisinger institutional review board-approved research if appropriate.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06495021
Lead sponsor
Geisinger Clinic
Responsible party
Sponsor
First posted
Jul 10, 2024
Start date
Dec 31, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
May 31, 2027 (estimated)
Last update
Aug 11, 2026

Study contacts

Margaret Moore, DO
Contact
Mmoore9@geisinger.edu
(570) 416-5435
Andrew Ackerman, MS
Contact
aackerman1@geisinger.edu
(570) 214-4215
Margaret Moore, DO
principal investigator · Physician

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion